175 related articles for article (PubMed ID: 9453323)
21. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden.
Eliasson M; Jansson JH; Nilsson P; Asplund K
J Hypertens; 1997 Apr; 15(4):349-56. PubMed ID: 9211169
[TBL] [Abstract][Full Text] [Related]
22. Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy.
Ridderstråle W; Ulfhammer E; Jern S; Hrafnkelsdóttir T
Hypertension; 2006 Apr; 47(4):686-91. PubMed ID: 16520399
[TBL] [Abstract][Full Text] [Related]
23. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism.
Chadarevian R; Bruckert E; Leenhardt L; Giral P; Ankri A; Turpin G
J Clin Endocrinol Metab; 2001 Feb; 86(2):732-7. PubMed ID: 11158038
[TBL] [Abstract][Full Text] [Related]
24. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study.
Higashi Y; Sasaki S; Nakagawa K; Ueda T; Yoshimizu A; Kurisu S; Matsuura H; Kajiyama G; Oshima T
J Am Coll Cardiol; 2000 Feb; 35(2):284-91. PubMed ID: 10676671
[TBL] [Abstract][Full Text] [Related]
25. The fibrinolytic system is not impaired in older men with hypertension.
DeSouza CA; Dengel DR; Rogers MA; Cox K; Macko RF
Hypertension; 1996 May; 27(5):1053-8. PubMed ID: 8621196
[TBL] [Abstract][Full Text] [Related]
26. Brachial artery flow-mediated vasodilation is correlated with coronary vasomotor and fibrinolytic responses induced by bradykinin.
Tarutani Y; Matsumoto T; Takashima H; Yamane T; Horie M
Hypertens Res; 2005 Jan; 28(1):59-66. PubMed ID: 15969256
[TBL] [Abstract][Full Text] [Related]
27. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.
Wright RA; Flapan AD; Alberti KG; Ludlam CA; Fox KA
J Am Coll Cardiol; 1994 Jul; 24(1):67-73. PubMed ID: 8006284
[TBL] [Abstract][Full Text] [Related]
28. Enhanced levels of tissue-type plasminogen activator in borderline hypertension.
Wall U; Jern C; Bergbrant A; Jern S
Hypertension; 1995 Nov; 26(5):796-800. PubMed ID: 7591020
[TBL] [Abstract][Full Text] [Related]
29. Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance.
Caballero AE; Bousquet-Santos K; Robles-Osorio L; Montagnani V; Soodini G; Porramatikul S; Hamdy O; Nobrega AC; Horton ES
Diabetes Care; 2008 Mar; 31(3):576-82. PubMed ID: 18083792
[TBL] [Abstract][Full Text] [Related]
30. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1.
Pahor M; Franse LV; Deitcher SR; Cushman WC; Johnson KC; Shorr RI; Kottke-Marchant K; Tracy RP; Somes GW; Applegate WB
Circulation; 2002 Jan; 105(4):457-61. PubMed ID: 11815428
[TBL] [Abstract][Full Text] [Related]
31. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
32. Hypo-fibrinolysis in patients with hypertension and elevated cholesterol.
Jansson JH; Johansson B; Boman K; Nilsson TK
J Intern Med; 1991 Apr; 229(4):309-16. PubMed ID: 1902868
[TBL] [Abstract][Full Text] [Related]
33. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
[TBL] [Abstract][Full Text] [Related]
34. Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition.
Higashi Y; Sasaki S; Nakagawa K; Kimura M; Sasaki S; Noma K; Hara K; Matsuura H; Goto C; Oshima T; Chayama K
J Cardiovasc Pharmacol; 2002 May; 39(5):668-76. PubMed ID: 11973410
[TBL] [Abstract][Full Text] [Related]
35. Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics.
Gismondi RA; Bedirian R; Pozzobon CR; Ladeira MC; Oigman W; Neves MF
Arq Bras Cardiol; 2015 Dec; 105(6):597-605. PubMed ID: 26465872
[TBL] [Abstract][Full Text] [Related]
36. In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction.
Eržen B; Šabovič M
Heart Vessels; 2013 Sep; 28(5):570-7. PubMed ID: 23001714
[TBL] [Abstract][Full Text] [Related]
37. Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance.
Jeng JR; Sheu WH; Jeng CY; Huang SH; Shieh SM
Am Heart J; 1996 Oct; 132(4):783-9. PubMed ID: 8831367
[TBL] [Abstract][Full Text] [Related]
38. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Brown NJ; Kumar S; Painter CA; Vaughan DE
Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570
[TBL] [Abstract][Full Text] [Related]
39. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
40. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
